Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07071714 | A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer | active not recruiting | Phase 2 | 103 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757165 | The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy(ESMGC) | recruiting | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Aug 11, 2026 |
| clinicaltrials |
| NCT03851614 | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors(DAPPER) | active not recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection(JUPITER 04) | active not recruiting | Phase 2 / Phase 3 | 427 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05518903 | Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma | recruiting | Phase 2 | 130 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06576115 | Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer | recruiting | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06577194 | Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) | active not recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07406633 | KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | recruiting | Phase 2 | 46 | Kumquat Biosciences Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07550088 | BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases | recruiting | Phase 2 | 17 | Darren Sigal, MDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07755124 | Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 140 | West China HospitalOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT03844620 | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05713838 | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | active not recruiting | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07162714 | SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer(STAR) | recruiting | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751055 | Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer(NEOCRTE2601) | recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT02965703 | Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06168812 | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | active not recruiting | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07043270 | 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC | recruiting | Phase 2 | 35 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07101666 | Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer(TNT-SHORT) | not yet recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07159204 | Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer(PILOT-BTC) | active not recruiting | Phase 2 | 61 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748611 | SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial | not yet recruiting | Phase 2 | 125 | Northwestern UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750041 | A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06447636 | Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07209215 | ctDNA-Informed Management of Early-Stage Rectal Cancer(ULTIMATE) | not yet recruiting | Phase 2 | 200 | University of California, DavisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05132504 | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 30 | Baylor College of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | recruiting | Phase 2 | 122 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07381634 | The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities | recruiting | Phase 2 | 134 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07564466 | A Study of SKB571 in Participants With Gastrointestinal Tumors | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07737600 | A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 316 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03878095 | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT06030622 | Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer(C3) | recruiting | Phase 1 / Phase 2 | 25 | State University of New York - Downstate Medical CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06210971 | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer | active not recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT06949098 | Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06949111 | Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer(Neo-Color) | recruiting | Phase 2 | 128 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02888743 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05217446 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer(SEAMARK) | active not recruiting | Phase 2 | 108 | PfizerINDUSTRY | 15 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2026source: clinicaltrials